Aatmaj Healthcare Limited

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,
Email: aatmajhealthcare@gmail.com; CIN: U85100GJ2014PLC079062,
Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

AHL/NSE/08/23 August 29, 2023

The Manager, Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051, Maharashtra, India.

Symbol: AATMAJ / ISIN: INE0OB201016

Dear Sir/Madam,

Sub: Outcome of Board meeting held on today i.e. on Tuesday, August 29, 2023, in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, at their Board Meeting held on today, i.e. on Tuesday, August 29, 2023, at the Registered Office of the Company situated at "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India and which was commenced at 06.00 pm and concluded at 08.45 pm has inter-alia considered and approved the following:

1. Considered, approved and taken on record the Audited Standalone Financial Statements of the Company for the Financial Year ended on March 31, 2023 along with Auditors' Report thereon;

   The said Financial Statements / Results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held today.

2. Approved Draft Director's Report along with annexures to the said report for the Financial Year ended on March 31, 2023, to form part of Annual Report 22-23.

3. Fixed the date of the 9th Annual General Meeting (AGM) of the Company to be held on Friday, September 29, 2023 at 4.00 p.m. (lST) through Video Conferencing (VC)/Other Audio Visual Means (OAVM)) in compliance with the applicable circulars of Ministry of Corporate Affairs (MCA) and SEBI;

4. Approved Notice of 9th Annual Ceneral Meeting (AGM) for the Financial Year ended on March 31, 2023. The copy of Notice of 9th Annual General Meeting and Annual Report for the financial year 2022-23 will be submitted to exchange as soon as the same be dispatched to the Shareholders of the Company through email.

5. Approved Schedule of Annual General Meeting w.r.t cut off date for remote e- voting, remote e-voting start date and end date. The schedule of AGM w.r.t cutt off date for remote e-voting will be submitted to exchange as soon as the same be dispatched to the Shareholders of the Company through email.

6. Approved appointment of M/s. K Parikh and Associates, Practicing Courpany Secretaries as Scrutinizer for E-Voting Process for AGM.

Aatmaj Healthcare Limited
Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,
Email: aatmajhealthcare@gmail.com; CIN: U85100GJ2014PLC079062,
Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

7. Approved reappointment of M/s. K Parikh and Associates, Practicing Courpany Secretaries, Vadodara, as Secretarial Auditor for Secretarial Audit of the Company for F.Y . 2023-24.

8. The Company has fixed Friday, 1st Septernber, 2023 as record date for the purpose of determining eligibility of Shareholders for sending of Annual Report for the F.y 22-23.

9. Considered and approved all other business as per agenda circulated.

Kindly take the above on record and oblige us.

Thanking you.

Yours faithfully,

For AATMAJ HEALTHCARE LIMITED

Tushar K Suvagiya
Managing Director
[DIN: 06802410]

AATMAJ HEALTHCARE LIMITED
VADODARA

Aatmaj Healthcare Limited

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India,
Email: aatmajhealthcare@gmail.com; CIN: U85100GJ2014PLC079062,
Website: jupiterhospitalvadodara.com, Contact No : 0265 2681568

AHL/NSE/08/23 August 29, 2023

The Manager, Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051, Maharashtra, India.

Symbol: AATMAJ / ISIN: INE0OB201016

Dear Sir/Madam,

Sub: Submission of Audited Standalone Financial Results of the Company for the Financial Year ended on March 31, 2023 along with Auditors' Report thereon.

Ref: Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to captioned subject and pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Audited Standalone Financial Results of the Company for the Financial Year ended on March 31, 2023, Auditors' Reports on the aforesaid Audited Financial Results.

Kindly take the above on record and oblige us.

Thanking you.

Yours faithfully,

For AATMAJ HEALTHCARE LIMITED

Tushar K Suvagiya
Managing Director
[DIN: 06802410]

AATMAJ HEALTHCARE LIMITED
VADODARA

BELA MEHTA & ASSOCIATES
CHARTERED ACCOUNTANTS

A - 204 Shree Siddhi Vinayak Complex, Opp Railway Station (West Side), Alkapuri VADODARA - 390 007.
(M) : 9824002556 | 9825800013, E-mail : bma_ca@rediffmail.com | vcbs2005@yahoo.co.in.

INDEPENDENT AUDITOR'S REPORT

To the Members of
AATMAJ HEALTHCARE LIMITED
(FORMERLY KNOWN AS AATMAJ HEALTHCARE PRIVITE LIMITED)

Report on the Audit of the Financial Statements

Opinion

We have audited the Financial Statements of AATMAJ HEALTHCARE LIMITED(FORMERLY KNOWN AS AATMAJ HEALTHCARE PRIVATE LIMITED) ("the Company"), which comprise the balance sheet as at 31st March 2023, and the statement of profit and loss, *(statement of changes in equity)* and statement of cash flows for the year then ended, and notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information [hereinafter referred to as "the Financial Statements"].

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, and its profit/loss, *(changes in equity)* and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

"Information Other than the Financial Statements and Auditor's Report Thereon"

The Company's Board of Directors is responsible for the other information. The other information comprises the [information included in the Director report, but does not include the Financial Statements and our auditor's report thereon.

Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Financial Statements that give a true and fair view of the financial position, financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

a. Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls

c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

d. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

e. Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in

- (i) Planning the scope of our audit work and in evaluating the results of our work; and
- (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143(3) of the Act, we report that:

    (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

    (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

    (c) The Balance Sheet, the Statement of Profit and Loss, (the Statement of Changes in Equity) and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.

    (d) In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

    (e) On the basis of the written representations received from the directors as on 31st March, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2023 from being appointed as a director in terms of Section 164(2) of the Act.

    (f) Since the Company's turnover as per last audited Financial Statements is less than Rs.50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs.25 Crores, the Company is exempted from getting an audit opinion with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls vide notification dated June 13, 2017;

    (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

a. The Company does not have any pending litigations which would impact its financial position.

b. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

c. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

d. i. The management has represented that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

   ii The management has represented, that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

   iii Based on such audit procedures which we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.

e. The company has not declared or paid any dividend during the year is in accordance with section 123 of the Companies Act 2013", Hence clause not applicable.

f. Proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 for maintaining books of account using accounting software which has a feature of recording audit trail (edit log) facility is applicable to the company with effect from April 1, 2023, and accordingly, reporting under rule 11(g) of Companies (Audit and Auditors) Rules, 2014 is not applicable for the financial year ended March 31, 2023.

For Bela Mehta & Associates
Chartered Accountants
FRN : 0101073W

BELA MEHTA & ASSOCIATES * VADODARA * Chartered Accountants

CA Shital S Parikh
Partner
M.No. 121609
UDIN :- 23121609BGUXBN1104

Date :- 29.082023 Place :- Vadodara

AATMAJ HEALTHCARE LIMITED
(Formerly Known As Aatmaj Healthcare Private Limited)
"Jupiter Hospital", Opp. "ICAI" Bhavan,
Sunpharma Atladara Road,Vadodara- GJ 390012 IN
CIN: U85100GJ2014PLC079062

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31/03/2023

In Lakhs except earning per share

Particulars	Note No.	For the Year Ended 31/03/2023	For the Year Ended 31/03/2022
Revenue from operations	3.7	2716.26	2180.88
Other income	3.8	2.64	-
Total Income		**2718.90**	**2180.88**
Expenses			
Cost of materials consumed	3.9	174.16	367.35
Purchases of Stock-in-Trade		-	-
Changes in inventories of finished goods work-in-progress and Stock-in-Trade		-	-
Employee benefits expense	4.0	465.72	394.42
Finance costs	4.1	89.51	24.15
Depreciation and amortization expense	4.2	68.77	43.45
Other expenses	4.3	1093.37	668.08
Total expenses		**1891.54**	**1497.45**
Profit before exceptional and extraordinary items and tax		827.36	683.43
Exceptional items		-	-
Profit before extraordinary items and tax		827.36	683.43
Extraordinary Items		-	-
Profit before tax		827.36	683.43
Tax expense:	4.4		
Current tax		219.21	175.00
Deferred tax		17.50	3.33
Profit/(loss) for the period from continuing operations		590.65	505.10
Profit/(loss) from discontinuing operations		-	-
Tax expense of discontinuing operations		-	-
Profit/(loss) from Discontinuing operations (after tax)		-	-
Profit/(loss) for the period		590.65	505.10
Earnings per equity share:	4.5		
Basic		3.64	37.41
Diluted		-	-

Notes attached to Audited Standalone Financial Results for the year ended March 31, 2023

1. The above standalone financial results of the company ("the statement") have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at its Meeting held on August 29, 2023 and have been subjected to audit by the statutory auditors of the company on which the auditors have been expressed an unmodified Opinion.

2. The Standalone Financial results has been prepared in accordance with recognition and measurement principles laid down in the As as prescribed under section 133 of the companies act, 2013 ("the Act") read with the companies (accounting standards) Rules, 2021, as amended from time to time and the provisions of the Companies Act, 2013, as applicable and guidelines issued by the securities and exchange board of india ('SEBI") and other recognized accounting principles and policies generally accepted in india to the extent possible.
These financial results are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with other relevant rules and circulars issued thereunder.

3. The company is engaged primarily in the business of Operating Multi Specialties Hospitals and all its operations are in india only. Accordingly, there is no separate reportable segment as per AS 17 on " Segment Reporting" in respect of Company.

BELA MEHTA & ASSOCIATES ★ VADODARA ★ Chartered Accountants

AATMAJ HEALTHCARE LIMITED ★ VADODARA

4. The Company was converted into a public limited Company pursuant to a special resolution passed by the shareholders at the Extra Ordinary General Meeting held on November 16, 2022 and consequentlythe name of the Company was changed to Aatmaj Healthcare Limited and a fresh certificate ofincorporation was issued by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli, datedDecember 06, 2022 bearing Corporate Identification Number U85100GJ2014PLC079062.

5. During the year, the Company vide its special resolution passed in the extra ordinary general meeting held at registered office dated 31st July, 2022 has allotted 40,50,000/- Equity Shares as fully paid up Bonus Shares in the ratio of 3:1 (i.e. Three Bonus Shares for every one Equity share held) by capitalisation of Free reserves of ` 4,05,00,000/- and on 7th November, 2022 has allotted 27,00,000/- Equity Shares as fully paid Bonus Shares in the ration of 1:2 (i.e. One Bonus Equity Shares of ` 10 each fully paid for every Two Equity shares of ` 10 each fully paid held by the shares of the company, by capitalisation of Free reserves of ` 2,70,00,000/-.

6. The nominal value of the equity shares of the company was sub divided from ` 10 each fully paid to ` 5 each fully paid thereby increased the fully paid no of equity shares from 81,00,000 to 1,62,00,000 equity shares of ` 5 each fully paid by way of passing of special resolution at the extra ordinary general meeting of the shareholders of the company held on 16th November, 2022.

7. Pursuant to the Initial Public Offer of Equity Shares as approved by the Members of the Company via resolution dated January 23, 2023, the Board of Directors, in their meeting held on June 26, 2023, has allotted total 64,00,000 Equity Shares ₹ 10/- each at price of ₹ 60/- per Equity Share to the successful allottees, whose list have been finalized by the Company, the Registrar to the issue and merchant banker in consultation with National Stock Exchange of India Limited.6. The Board of Directors had, in its meeting held on January 23, 2023, approved to create, offer, issue and allot not exceeding 64,00,000 equity shares via Initial Public Offer of face value of ₹ 5/- each fully paid for cash at a price of ₹ 60 per equity share aggregating ₹ 38,40,00,000 Crores as approved by the Board of Directors in consultation with the Merchant Banker. The Members of the Company had also approved the issue at their Extra-ordinary General Meeting held on February 15, 2023.Pursuant to the authority granted by the Members of the Company, the Board of Directors appointed Nirbhay Capital Services Private Limited as Lead Manager and Link Intime India Private Limited as Registrar to the Issue and Share Transfer Agent for the proposed Public Issue. The Company applied to National Stock Exchange of India Limited ("NSE") for in-principle approval for listing its equity shares on the Emerge Platform of the NSE. National Stock Exchange of India Limited has, vide its letter dated J u n e 1 , 2023 granted it's In Principle Approval to the Company. The Company had filed Prospectus to the Registrar of the Company, Ahmedabad on June 13, 2023.The Public Issue was opened on Monday, June 19, 2023 and closed on Wednesday, June 21, 2023. The Basis of Allotment was finalized by Company, Registrar to the issue and merchant banker in consultation with the NSE on June 26, 2023. The Company has applied for listing of its total equity shares to NSE and it has granted its approval vide its letter dated June 28, 2023.
The trading of equity shares of the Company commenced w.e.f. June 30, 2023 at Emerge Platform of National Stock Exchange of India Ltd. (NSE)

8. Audited statements of Assets and liabilities and Statement of Cash Flow are attached as "Annexure A' and "Annexure B" respectively.

9. Previous year's/period's figures have been regrouped/reclassified whenever necessary.

For Aatmaj Healthcare Limited

Dr. Tushar Suvagiya
Managing Director
DIN : 06802410

AATMAJ HEALTHCARE LIMITED VADODARA

BELA MEHTA & ASSOCIATES VADODARA Chartered Accountants

Date : 29/08/2023
Place : Vadodara

AATMAJ HEALTHCARE LIMITED
(Formerly Known As Aatmaj Healthcare Private Limited)
"Jupiter Hospaital" , Opp. "ICAI" Bhavan,
Sunpharma Atladara Road, Vadodara GJ 390012 In
CIN: U85100GJ2014PLC079062
Annexure A: Audited Standalone Statement of Assets and Liabilities

In Lakhs

Particulars	Note No.	As at 31/03/2023	As at 31/03/2022
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	2.1	810.00	135.00
Reserves and surplus	2.2	607.77	692.11
Money received against share warrants		-	-
		1417.77	827.11
Share application money pending allotment		-	-
Non-current liabilities			
Long-term borrowings	2.3	179.27	72.49
Deferred tax liabilities (Net)	2.4	67.17	49.67
Other Long term liabilities		-	-
Long-term provisions		-	-
		246.44	122.17
Current liabilities			
Short-term borrowings	2.5	990.55	445.03
Trade payables	2.6		
Total outstanding dues of micro enterprises and small enterprises		-	-
Total outstanding dues of creditors other than micro enterprises and small enterprises		211.95	163.77
Other current liabilities	2.7	8.99	10.45
Short-term provisions	2.8	225.02	178.81
		1436.50	798.06
TOTAL		**3100.71**	**1747.34**
ASSETS			
Non-current assets			
Property, Plant and Equipment and Intangible Assets			
Property, Plant and Equipment	2.9	1113.30	1081.23
Intangible assets	3.0	3.78	6.23
Capital work-in-progress		-	-
Intangible assets under development		-	-
		1117.08	1087.46
Non-current investments	3.1	-	0.30
Deferred tax assets (net)		-	-
Long-term loans and advances		-	-
Other non-current assets		-	-
		1117.08	1087.76
Current assets			
Current investments		-	-
Inventories	3.2	40.05	40.50
Trade receivables	3.3	1782.61	509.61
Cash and cash equivalents	3.4	31.69	18.07
Short-term loans and advances	3.5	108.51	63.62
Other current assets	3.6	20.77	27.78
		1983.62	659.58
Accounting Policies and Notes on Accounts	1.0		
TOTAL		**3100.71**	**1747.34**

BELA MEHTA & ASSOCIATES
VADODARA
Chartered Accountants

AATMAJ HEALTHCARE LIMITED
VADODARA

AATMAJ HEALTHCARE LIMITED
(Formerly Known as Aatmaj Healthcare Private Limited)
"Jupiter Hospital", Opp. "ICAI" Bhavan,
Sunpharma Atladara Road, Vadodara GJ 390012 IN
CIN: U85100GJ2014PLC079062

Annexure B : Audited Standalone Cash Flow Statement

In ` Lakhs

Particular	31/03/2023	31/03/2022
Cash Flows from Operating Activates		
Net Profit Before Tax and Extra Ordinary Items	827.36	683.43
Adjustment For		
Depreciation	68.77	43.45
Foreign Exchange		
Gain Or Loss Of Sale Of Fixed Assets		
Gain Or Loss Of Investment		
Finance Cost	89.51	24.15
Dividend Income		
Other Adjustment Of Non Cash Item		
Other Adjustment To Reconcile Profit		
Total Adjustment To Profit/Loss (A)	**158.29**	67.60
Adjustment For Working Capital Change		
Adjustment For Increase/Decrease In Inventories	0.45	-20.00
Adjustment For Increase/Decrease In Trade Receivables	-1273.00	-452.56
Adjustment For Increase/Decrease In Other Current Assets	-37.68	-38.11
Adjustment For Increase/Decrease In Trade Payable	48.18	-6.00
Adjustment For Increase/Decrease In Other Current Liabilities	544.06	373.76
Adjustment For Provisions	46.20	172.02
Total Adjustment For Working Capital (B)	**-671.99**	**29.12**
Total Adjustment To Reconcile Profit (A+B)	**-513.70**	**96.72**
Net Cash Flow From (Used In) Operation	**313.66**	**780.15**
Dividend Received		
Interest Received		
Interest Paid		
Income Tax Paid/ Refund	219.21	175.00
Net Cash Flow From (Used In) Operation Before Extra Ordinary Items	**532.87**	**955.15**
Proceeds From Extra Ordinary Items		
Payment For Extra Ordinary Item		
Net Cash Flow From Operating Activities	**532.87**	955.15
Cash Flows From Investing Activities		
Proceeds From Fixed Assets		
Proceeds From Investment Or Equity Instruments	-0.30	0.00
Purchase Of Fixed Assets	96.40	310.26
Purchase Of Investments Or Equity Instruments	0.00	0.30
Interest Received		
Dividend Received		
Cash Receipt From Sale Of Interest In Joint Venture		
Cash Payment To Acquire Interest In Joint Venture	43.00	22.00
Cash Flow From Losing Control Of Subsidiaries		
Cash Payment For Acquiring Control Of Subsidiaries	0.00	4.00
Proceeds From Govt. Grant		
Other Inflow/Outflow Of Cash		
Net Cash Flow From (Used In) In Investing Activities Before Extra Ordinary Items	**-141.70**	-336.56
Proceeds From Extra Ordinary Items		
Payment For Extra Ordinary Item		
Net Cash Flow From (Used In) In Investing Activities	**-141.70**	-336.56
Cash Flows From Financial Activities		
Proceeds From Issuing Shares	0.00	0.00
Proceeds From Issuing Debenture /Bonds/Notes		
Redemption Of Preference Share		
Redemption Of Debenture		
Proceeds From Other Equity Instruments		
Proceeds From Borrowing	-32.59	-344.96
Repayment Of Borrowing	344.96	310.43
Dividend Paid		
Interest Paid		
Income Tax Paid/Refund		
Net Cash Flow From (Used In) In Financial Activities Before Extra Ordinary Items	-377.55	-655.39
Proceeds From Extra Ordinary Items		
Payment For Extra Ordinary Item		
Net Cash Flow From (Used In) In Financial Activities	-377.55	-655.39
Net Increase (Decrease) In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes	13.62	-36.80
Effect Of Exchange Rate Change On Cash And Cash Equivalents		
Net Increase (Decrease) In Cash And Cash Equivalents	13.62	-36.80
Cash And Cash Equivalents At Beginning Of Period	18.07	54.87
Cash And Cash Equivalents At End Of Period	31.69	18.07

BELA MEHTA & ASSOCIATES Chartered Accountants VADODARA

AATMAJ HEALTHCARE LIMITED VADODARA